На главную
Результаты поиска “U.S. Pharmaceutical Sales Statistics” за 2015
Probability-based forecasting for U.S. generic drug sales.
 
03:28
Value of Insight VoiConsulting.com.
Просмотров: 370 Value Of Insight
Bernie Sanders' Thoughts on Drug Company Fraud and High Cost of Medicine in America
 
07:13
On May 23, 2012, Senator Bernie Sanders criticized the exorbitant prices Americans pay for prescription drugs and the enormous amount of fraud that takes place within the pharmaceutical industry. Link: http://www.sanders.senate.gov/newsroom/press-releases/sanders-crack-down-on-pharmaceutical-fraud Abbott Labs, which agreed last month to pay $1.6 billion for illegally marketing the anti-seizure drug Depakote. The New York Times said the company also agreed to plead guilty to one misdemeanor charge for violating the Food, Drug and Cosmetic Act for misbranding. Abbott Labs agreed to pay $421 million in 2010, along with two smaller companies, to settle charges that they deliberately spiked drug costs by up to 10 times the actual cost in order to boost reimbursements from Medicare and Medicaid. Pfizer, which paid $49 million to settle charges that a subsidiary defrauded the Medicaid program by overcharging for the cholesterol-lowering drug Lipitor. A division of Pfizer pleaded guilty to two felonies and agreed to pay $430 million to settle charges that it fraudulently promoted the drug Neurontin for a string of unapproved uses. GlaxoSmithKline, which in 2011 reached an "agreement in principle" to pay $3 billion to conclude the company's most significant ongoing federal government investigations into illegal sales and marketing practices for a diabetes drug that was severely restricted last year after it was linked to heart risks. Merck, which in 2009 reached a $670 million settlement for fraud on patients and Medicare/Medicaid involving a conspiracy with hospitals to give the elderly cheaper drugs but charging them for the more expensive product prescribed by the patients' doctors. Merck last year pleaded guilty to a criminal misdemeanor charge and paid a $950 million settlement for illegally promoting Vioxx for rheumatoid arthritis before that use was approved. Vioxx was linked to thousands of heart attacks and sudden cardiac deaths before it was pulled from the market in 2004. Johnson & Johnson last year illegally marketed Risperdal, an anti-psychotic medication, to nursing home patients, and paid over $2 billion in fines, a mere 6.3 percent of sales from the drug. www.ouramazingworld.org FB.com/ouramazingworldd Twitter.com/OAWoww
Просмотров: 1682 Our Amazing World
The Truth About Cancer: A Global Quest - Episode 1
 
01:58:50
!! Free "A Global Quest" Episode 1!! "The True History of Chemotherapy & The Pharmaceutical Monopoly" If you would like to support our mission and own all Episodes of this eye-opening Docu-Series, please follow this link: http://bit.ly/agq-silver-order --------------------------------------------------- Welcome to Episode 1 of "The Truth About Cancer: A Global Quest". This Episode is about the true history of Chemotherapy and the pharmaceutical monopoly. We welcome you to watch this Episode completely free. To watch Episode 2 of "A Global Quest" docu-series for FREE, click here: https://youtu.be/VK_sX5ko8SE Join TTAC's 1M+ FB fans: http://bit.ly/agq-fb-ttac Follow us on PINTEREST: http://bit.ly/agq-pinterest-ttac Find us on INSTAGRAM: http://bit.ly/agq-ig-ttac Visit our website: http://bit.ly/agq-website-ttac Our mission is to educate the world, expose lies & empower people with life-saving knowledge. Help us and share the truth, by clicking the SHARE button above! -------------------------------------------------- About The Truth About Cancer -------------------------------------------------- The Truth About Cancer’s mission is to inform, educate, and eradicate the pandemic of cancer in our modern world. Every single day, tens of thousands of people just like you are curing cancer (and/or preventing it) from destroying their bodies. It’s time to take matters into your own hands and educate yourself on real cancer prevention and treatments. It could save your life or the life of someone you love. ---------------------------------------------------------------------- Inside The Truth About Cancer Docu-Series --------------------------------------------------------------------- Doctors, researchers, experts, and survivors show you exactly how to prevent and treat cancer in our 3 original docu-series: "The Quest For The Cures”, “The Quest For The Cures Continues”, “The Truth About Cancer: A Global Quest”, and on our website: http://bit.ly/agq-website-ttac In our docu-series, you’ll travel with Ty Bollinger who lost both his mother and father to cancer (as well as 5 other family members). Ty travels the country and the globe and sits down with the foremost doctors, researchers, experts, and cancer conquerers to find out their proven methods for preventing and treating cancer. Please join our email list to be notified of all upcoming events (including free airings of our docu-series): http://bit.ly/join-ttac-mission Learn more about our latest docu-series “The Truth About Cancer: A Global Quest” here: http://bit.ly/free-signup-agq --------------------------------------- About Ty Bollinger --------------------------------------- Ty Bollinger is a devoted husband, father, a best-selling author, and a Christian. He is also a licensed CPA, health freedom advocate, cancer researcher, former competitive bodybuilder, and author of the best-selling book "Cancer - Step Outside the Box," which has sold over 100,000 copies worldwide. After losing his mother and father and several family members to cancer, Ty’s heartbreak and grief coupled with his firm belief that chemotherapy, radiation, and surgery were the NOT the most effective treatments available for cancer patients led him on a path of discovery. He began a quest to learn everything he possibly could about alternative cancer treatments and the medical industry. What he uncovered was shocking. On his journey, he’s interviewed cutting-edge scientists, leading alternative doctors, and groundbreaking researchers to learn about hidden alternative cancer treatments. What he uncovered help to create The Truth About Cancer and its 3 awe-inspiring docu-series’: ”The Quest for The Cures”, “The Quest For The Cures Continues”, and “The Truth About Cancer: A Global Quest.” Ty has touched the hearts and changed the lives of thousands of people around the world. Ty speaks frequently at conferences, local health group meetings, churches, and is a regular guest on multiple radio and TV shows and writes for numerous magazines and websites. ----------------------------------------------------------------------------------------------------------------
Просмотров: 3497783 The Truth About Cancer
Biopharmaceutical Company Beats on Earnings on Growing Sales of Depression Drug
 
00:50
Drug maker Bristol Myers (BMY) posted earnings of $0.71 per share on Tuesday, beating analyst estimates. Revenue was also higher than expected, coming in at $4.04B - a 6 percent increase on last year's numbers.The bio-pharmaceutical company benefited from increased sales of its depression treatment Abilify this quarter, but is facing competition from similar copies of the drug in the US. The New York based company was hit by the strong dollar but remains optimistic about its pipeline of immunotherapy cancer drugs and latest Hepatitis C treatments. Sales of the company's latest cancer drug Opdivo missed Wall Street expectations which knocked the stock price in this morning. Subscribe to TheStreetTV on YouTube: http://t.st/TheStreetTV For more content from TheStreet visit: http://thestreet.com Check out all our videos: http://youtube.com/user/TheStreetTV Follow TheStreet on Twitter: http://twitter.com/thestreet Like TheStreet on Facebook: http://facebook.com/TheStreet Follow TheStreet on LinkedIn: http://linkedin.com/company/theStreet Follow TheStreet on Google+: http://plus.google.com/+TheStreet
Просмотров: 85 TheStreet: Investing Strategies
'Big pharma profiteering must be stopped' – Doctors Without Borders chief
 
02:18
The 2014 Ebola epidemic highlighted the global threat of disease. And while the need for new drugs and vaccines is clear, the research is often driven by profit. How can these opposites be reconciled, and what challenges do aid organisations face in the field? Oksana is joined by Dr Joanne Liu, the International President of Doctors Without Borders, for a dose of these issues. WATCH FULL INTERVIEW HERE: https://youtu.be/_zyEKRzrO_0 RT LIVE http://rt.com/on-air Subscribe to RT! http://www.youtube.com/subscription_center?add_user=RussiaToday Like us on Facebook http://www.facebook.com/RTnews Follow us on Twitter http://twitter.com/RT_com Follow us on Instagram http://instagram.com/rt Follow us on Google+ http://plus.google.com/+RT Listen to us on Soundcloud: https://soundcloud.com/rttv RT (Russia Today) is a global news network broadcasting from Moscow and Washington studios. RT is the first news channel to break the 1 billion YouTube views benchmark.
Просмотров: 8273 RT
FDA cracks down on supplements
 
03:54
For almost 5 years, the FDA has been attacking Daniel Smith of Spokane Washington for selling a mineral supplement that purifies water and has been used in places like Africa by the Red Cross to prevent Malaria. The product is called MMS (Miracle Mineral Solution), and the active ingredient is sodium chlorite, a common mineral that is even used in some municipalities in the U.S. to purify water instead of chlorine. Daniel Smith will face a trial in less than 30 days, the culmination of close to 5 years of legal battles, that could result in him spending 37 years in prison if convicted. Why? Because the FDA has not approved his product for health claims. Has the product killed anyone? No. Do FDA approved products kill anyone? Yes. According to statistics published by medical authorities themselves, FDA prescription drugs are one of the top causes of death in the United States, and probably the #1 cause of death among Americans today. An older study published by the Journal of the American Medical Association in 1998 stated that 106,000 people died from prescription drugs every year, and the CDC has previously stated that overdoses of FDA-approved prescription opioid pain relievers now exceed deaths involving heroin and cocaine combined. By contrast, a Government Accounting Office (GAO) report in 2013 found ZERO deaths due to dietary supplements. Most of the American public is probably largely unaware that the FDA’s mission is NOT to protect American’s health, but to approve pharmaceutical drugs. Most of its funding comes from the pharmaceutical industry itself, in the drug approval process. The cost to get a drug approved by the FDA is in the hundreds of millions of dollars. The revolving door policy between government health officials and pharmaceutical company executives has been well documented. There are only a handful of pharmaceutical companies that ever get drugs approved in the U.S. market, and if one were to develop a novel cure or drug outside of one of these handful of companies, the only hope they would have to get their product to market would be to sell their business and/or patent to one of these companies the FDA works with. - See more at: http://healthimpactnews.com/2015/fda-attacks-man-for-selling-supplement-that-has-healed-tens-of-thousands-facing-37-years-in-prison/#sthash.nLRBoVpH.dpuf -~-~~-~~~-~~-~- Please watch: "Hillary Uses Dallas Tragedy As a Decoy" https://www.youtube.com/watch?v=dfF1SmplWYY -~-~~-~~~-~~-~-
Просмотров: 247 OpenMind
US Anthrax Drugs
 
01:40
Washington, DC Oct. 26, 2001 APTN 1. ws executives coming to microphone 2. cutaway press 3. SOUNDBITE: Chief Operating Officer of GlaxoSmithKline, Bob Ingram, "We have committed that we will work closely with the Food and Drug Administration to expedite the approval for the use of two of our antibiotics, Augmentin and Amoxil against the anthrax strain, and if those are approved we will then donate those free of charge to anyone infected or exposed to anthrax. Secondly, we've sent in our proposal yesterday to commit to supply smallpox vaccine within that one year period we've condensint I hope everyone understands from five to one eight years down to one as several other companies are committing to." 4. ws press 5. SOUNDBITE: Peter Goland, CEO Bristol-Meyers Squibb, "In my company's case, Briston Myers Squibb, we're offering to make our antibiotic available, Tequin, assuming it's approved for the anthrax indication, at no cost to anyone who contracts that illness. Secondly, we're offering 20 to 25 scientists who have experience in antibacterial in voroligy who can work as part of a bioterrorism team to address the country's threats and needs at this time." 6. cutaway press 7. ws executives walking away STORYLINE: Leaders of major pharmaceutical companies detailed steps the companies have taken since September 11 to assist the government's efforts to protect the public health, including providing the public with free anthrax drugs which are alternatives to Cipro. The Pharmaceutical Research and Manufacturers of America (PhRMA) said the companies are coordinating their efforts as part of a newly-created Task Force on Emergency Preparedness. Pharmaceutical companies outlined a wide-range of efforts they are working on to meet new threats at a meeting with Health and Human Services Secretary Tommy Thompson in Washington Friday. Initiatives include offers of free antibiotics to authorities to treat people infected by or exposed to anthrax; offers to develop and manufacture a smallpox vaccine; pledges to increase production of certain medicines as needed; giving government scientists access to company laboratories and production facilities; making company scientists available to work in government facilities as needed. The PhRMA represents the country's leading research-based pharmaceutical and biotechnology companies. The companies are offering an alternative to Cipro, the most popular anthrax drug on the market. The patent-holding maker of Cipro, Bayer Corp., has been ramping up retail production to 100 million tablets by mid-January, according to company officials. That is in addition to the 100 million pills the company agreed to supply to the U.S. government for emergency use at a cost of 95 cents apiece. The government is stockpiling Cipro for use where it is most needed in a national emergency. A jump of nearly 50 percent in prescriptions nationwide for Cipro shows that many doctors and patients are shrugging off government pleas against stockpiling for personal use, medical and industry experts say. In the New York City area, prescriptions nearly tripled, drug marketing data indicate. Spurred by news reports on potential bioterrorism, sales of the antibiotic began climbing right after the Sept. 11 air attacks and weeks before the first news of an anthrax case on Oct. 4, according to a national marketing consultant that surveys pharmaceutical retailers. The numbers are apt to rise more still as they are released in coming weeks, because the latest data go only as far as Oct. 12 - before the last anthrax deaths and widespread Cipro treatment for postal workers. Increases were especially heavy in Washington too, which together with New York suffered the brunt of the Sept. 11 attacks. You can license this story through AP Archive: http://www.aparchive.com/metadata/youtube/a50f91724d04280e039ad4aea9dbc2cc Find out more about AP Archive: http://www.aparchive.com/HowWeWork
Просмотров: 107 AP Archive
How Does The FDA Approve New Drugs?
 
03:29
How Powerful Is Russia? http://bit.ly/1Ov9jE1 » Subscribe to NowThis World: http://go.nowth.is/World_Subscribe For decades, Cuba's been under an embargo, but its relations with the U.S. are now easing. So how powerful is the communist nation? Learn More: Castro steps down as Cuban leader http://news.bbc.co.uk/2/hi/americas/7252109.stm "Cuba's ailing leader Fidel Castro has announced he will not accept another term as president, ending the communist revolutionary's 49 years in power." Anuario Estadistico de Cuba http://www.one.cu/aec2014/07%20Empleo%20y%20Salarios.pdf El presente capítulo tiene como objetivo mostrar la evolución de indicadores relacionados con el empleo, los salarios, la protección del trabajo, la seguridad social y la asistencia social. Cuban Immigrants in the United States http://www.migrationpolicy.org/article/cuban-immigrants-united-states "Cuba has occupied a unique place in U.S. immigration law and policy as a result of fraught political relations and geographic proximity between the two countries." US-Cuba agree commercial flights deal http://www.bbc.com/news/world-us-canada-35117319 "The United States and Cuba have agreed to restore regular commercial flights, in a deal that could jumpstart economic relations between the two countries." Music Track Courtesy of APM Music: "Concentration" _________________________ NowThis World is dedicated to bringing you topical explainers about the world around you. Each week we’ll be exploring current stories in international news, by examining the facts, providing historical context, and outlining the key players involved. We’ll also highlight powerful countries, ideologies, influential leaders, and ongoing global conflicts that are shaping the current landscape of the international community across the globe today. More from NowThis: » Tweet @NowThisNews on Twitter: http://go.nowth.is/News_Twitter » Subscribe to NowThis News: http://go.nowth.is/News_Subscribe » Like NowThis World on Facebook: https://go.nowth.is/World_Facebook » Connect with Judah: Follow @judah_robinson on Twitter – Facebook: http://go.nowth.is/LikeJudah » Connect with Versha: Follow @versharma on Twitter – Facebook: http://go.nowth.is/LikeVersha http://www.youtube.com/nowthisworld Special thanks to Aneeta Akhurst for hosting TestTube!
Просмотров: 82487 NowThis World
POLICE DEPT. EXPOSE BIG PHARMA SALARIES BUT, WHAT IF IT WAS US?
 
06:51
From an article on Activist Post- fair use: This is great. Great in the sense someone is actually DOING something to combat this constant and ever growing TYRANNY. This police dept. exposed the names, e-mail addresses, and phone numbers of some of America's biggest drug dealers. Great job! I agree absolutely and 100%. So, what's my problem? I thought this goverment was going after whistleblowers? Like Snowden and what's his...err...HER name? I cannot help but, wonder, if WE did this, would we just make the pages of Activist Post or would we be asking Snowden to scoot over?
Просмотров: 18 Medical Menudo420
How much does it cost to develop a new drug?
 
02:27
Pharmaceutical companies and civil society confront their calculations for the cost of a new drug. Footage: Anne Vigna Edition: Miguel Angel Gavilanes Medicamentalia 2015
Просмотров: 228 Fundación Civio
Pharmaceutical Company Cuts Outlook Due to Patent Expirations and Strong Dollar
 
00:48
Pfizer's (PFE) new drugs pipeline gave their first quarter earnings a boost on Tuesday. The company beat estimates posting profits of $2.4B or $0.51 per share. Revenue was down on last year's numbers, coming in at $10.86 billion. The pharmaceuticals giant was hurt by the strong dollar and a wave of patent expirations. Pfizer cut its full year outlook for 2015 and lowered revenue forecasts to to $46.5 billion. The company saw a 44% increase in global vaccine revenue and agreed to buy injectable drugs maker Hospira for $16 billion back in February. Pfizer stock is up around 11 percent this year. Subscribe to TheStreetTV on YouTube: http://t.st/TheStreetTV For more content from TheStreet visit: http://thestreet.com Check out all our videos: http://youtube.com/user/TheStreetTV Follow TheStreet on Twitter: http://twitter.com/thestreet Like TheStreet on Facebook: http://facebook.com/TheStreet Follow TheStreet on LinkedIn: http://linkedin.com/company/theStreet Follow TheStreet on Google+: http://plus.google.com/+TheStreet
Просмотров: 88 TheStreet: Investing Strategies
GSK's challenging year | FT Business
 
04:35
► Subscribe to the Financial Times on YouTube: http://bit.ly/FTimeSubs Sir Andrew Witty, chief executive of GlaxoSmithKline, talks to the FT's pharmaceuticals correspondent Andrew Ward about a challenging past year for the drugmaker and his strategy for returning it to growth. ► FT Business: http://bit.ly/1KUK08s ► UK Business & Politics: http://bit.ly/1AXNyGS ► SABMiller Looks to craft beer for growth: http://bit.ly/1IyNpLK For more video content from the Financial Times, visit http://www.FT.com/video Twitter https://twitter.com/ftvideo Facebook https://www.facebook.com/financialtimes
Просмотров: 3124 Financial Times
Pfizer, Allergan Create Largest Pharmaceutical Merger
 
01:44
Pfizer and Allergan are set to reach a $150 billion deal that would create the world's largest drug maker in terms of sales, according to the Wall Street Journal.
Просмотров: 262 CBN - The Christian Broadcasting Network
Wedding attracts foreign visitors in large numbers
 
03:03
(26 Apr 2011) SHOTLIST 1. Tower of London with tour boat sailing past on river in foreground 2. Tower of London walls and buildings 3. Tourists clambering down stairs on Tower of London rampart 4. Reverse shot of group of American tourists, all dressed identically in red outfits and hats with American flags, looking at Tower of London 5. Front view of Americans standing in line 6. Tourists displaying hands all with identical rings, copies of Kate Middleton's engagement ring 7. SOUNDBITE: (English) Marcia Anderson, 49-year-old pharmaceutical sales representative from Oklahoma City, United States: "London's just a great city. Great history - obviously the Tower and everything here. But then to have the royals and to be able to come and see all the royal things...." SOUNDBITE: (English) Mary Boepple, 49-year-old retiree from Cyprus, Texas, United States - and twin sister of Marcia Anderson: "The thousands of years of history is what's exciting and walking in their (the royal family's) footsteps and enjoy the places that we know that they've been." 8. Tourists walking along Tower of London concourse 9. Tourist taking photograph 10. Tourists walking along walls of Tower of London 11. SOUNDBITE: (English) John Keohane, Chief Yeoman Warder of the Tower of London: "There's so much tradition and this is what I think - especially our visitors from the United States or (elsewhere) abroad - come here to see. They want to come and see all what the British monarchy is all about and why it's so important to all of us that live here in this great country." 12. Group of German tourists looking at guide book 13. Tourists' hands and guide book 14. SOUNDBITE: (German) Jonathan Soenenan, 30 year-old tourist from Berlin, Germany: "We hadn't planned to come here for the royal wedding and it's a coincidence that it's happening while we're here. There's lots going on that we didn't expect, but I might go down on the day and wave at the royal couple!" 15. Tourists walking along concourse 16. SOUNDBITE: (Italian) Massimo Caneva, tourist from Treviso, Italy: "It's fun for the children, especially to see the crown jewels, as well as other things connected to queens and kings, and so they're having a great time." 17. Caneva and family walking away from camera 18. Long shot of Tower of London concourse with tourists walking 19. Tourist taking photograph next to river with Tower of London in background - pans right to show group posing for photograph in front of Tower Bridge 20. Tourists with camera looking at river 21. SOUNDBITE: (English) Jacqueline French, spokesperson for London and Partners, the official promotional agency for London: "What we are hoping is that the royal wedding will really put a spotlight on London. There's an approximate four (b) billion people will be watching the wedding overseas. We've got the queen's jubilee next year, as well as the 2012 Olympic and Paralympic Games. And all of this will create a sense of fun and great atmosphere in London that hopefully people will want to be a part of." 22. Group of tourists by river with map and camera 23. Wide shot of Tower Bridge and River Thames with tourists walking STORYLINE: The British capital is witnessing a boom in tourism ahead of Friday's royal wedding. Some London landmarks are reporting swelling numbers of international visitors, many of whom say they're here primarily because of Prince William and Kate Middleton's 29 April nuptials. Tourists were flocking to the Tower of London on Tuesday. The iconic landmark by the River Thames, with its 900 years of royal history, is a regular stop on the tourist trail. But numbers are definitely up, according to officials. They wore matching red hats, complete with American flags, and identical red outfits. You can license this story through AP Archive: http://www.aparchive.com/metadata/youtube/140aeab52eef79898706b0d8f244b330 Find out more about AP Archive: http://www.aparchive.com/HowWeWork
Просмотров: 38 AP Archive
Addiction
 
05:42
What causes addiction? Easy, right? Drugs cause addiction. But maybe it is not that simple. This video is adapted from Johann Hari's New York Times best-selling book 'Chasing The Scream: The First and Last Days of the War on Drugs.' For more information, and to take a quiz to see what you know about addiction, go to www.chasingthescream.com Support us on Patreon so we can make more stuff: https://www.patreon.com/Kurzgesagt?ty=h Get the music of the video here: https://soundcloud.com/epicmountain/addiction https://epicmountainmusic.bandcamp.com/track/addiction An interactive version of this video: http://www.addiction.mobydigg.de (works on mobile) Or follow us on social media or reddit: http://kurzgesagt.org https://www.reddit.com/r/kurzgesagt https://www.facebook.com/Kurzgesagt https://twitter.com/Kurz_Gesagt THANKS A LOT TO OUR LOVELY PATRONS FOR SUPPORTING US: T0T0S, Ryan OHoro, Matthieu de Canteloube, Vince, Thomas Shiels, Brian David Henderson, Jim Yang, Arnav Guleria, Clemens, Tahseen Mushtaque, Jochen, Vahur S, Harry, BurmansHealthShop, Nils Caspar, Holger Fassel, Jackson R Hanna, Pascal de Reuck, ByeongWook Lee, Guus Ketelings, Franko Papić, Thalia, Narat, Suchartsunthorn, Lorenz Zahn, Brian Aparicio, Jörg Vogelsang, Rashed Ali, Darwin Ranzone, Tyler Thornton, David Pfister, Han Saini, Ute Moll, Ioanna Bischinioti, Jenny Zhou, Vince Babbra. Avi Yashchin, Dan Cortes, Matt K, Phiroze Dalal, Marcelo Fernandes de Souza Filho, A La Mode, Tom Wardrop, Shawn Marincas, Pontus Attåsen, Paul, Marc Dumont, Robert McKone, Todd Binkley, Matthew von der Ahe, Thomas Russell, Erick, Vivek Kotecha, Artur Szczypta, Jeff Fellows, Daniel Duffee, Konstantin Shabashov, Tim drake, Mike Galles, Evgenia Yigitalieva, Vrm Vee Are Em, Timothy Noble Everything We Think We Know About Addiction Is Wrong Help us caption & translate this video! http://www.youtube.com/timedtext_cs_panel?c=UCsXVk37bltHxD1rDPwtNM8Q&tab=2
Просмотров: 17559105 Kurzgesagt – In a Nutshell
Healthcare: Top 3 Drug Approvals of 2015 *** INDUSTRY FOCUS ***
 
21:18
This episode we're highlighting what we think are the most significant, needle-moving drugs to hit the market this year. This podcast was recorded on 12/2/2015. Imagine owning Amazon.com (up over an insane 4,000% since 2001) when Internet sales rendered big-box retailers obsolete... Now an industry 99% of us use daily is set to implode... And 3 established companies are positioned to take advantage. Click http://bit.ly/1zQXjzy for a stunning presentation. ------------------------------------------------------------------------ Subscribe to The Motley Fool's YouTube Channel: http://www.youtube.com/TheMotleyFool Or, follow our Google+ page: https://plus.google.com/+MotleyFool/posts Inside The Motley Fool: Check out our Culture Blog! http://culture.fool.com Join our Facebook community: https://www.facebook.com/themotleyfool Follow The Motley Fool on Twitter: https://twitter.com/themotleyfool
Просмотров: 147 The Motley Fool
Global Cervical Cancer Drug Industry 2015 Market Research Report
 
00:31
Big Market Research “Global Cervical Cancer Drug Industry” Size, Share, Industry Trends, Demand, Insights, Analysis, Research, Report, Opportunities, Company Profiles, Forecast. The Global Cervical Cancer Drug Industry 2015 Deep Market Research Report is a professional and in-depth study on the current state of the Cervical Cancer Drug industry. The report provides a basic overview of the industry including definitions, classifications, applications and industry chain structure. The Cervical Cancer Drug market analysis is provided for the international markets including development trends, competitive landscape analysis, and key regions development status. Development policies and plans are discussed as well as manufacturing processes and cost structures are also analyzed. This report also states import/export consumption, supply and demand Figures, cost, price, revenue and gross margins. Read more details at: http://www.bigmarketresearch.com/global-cervical-cancer-drug-industry-2015-deep-research-report-market The Global Cervical Cancer Drug Industry, report focuses on global major leading industry players providing information such as company profiles, product picture and specification, capacity, production, price, cost, revenue and contact information. Upstream raw materials and equipment and downstream demand analysis is also carried out. The Cervical Cancer Drug industry development trends and marketing channels are analyzed. Finally the feasibility of new investment projects are assessed and overall research conclusions offered. With 164 tables and figures the report provides key statistics on the state of the industry and is a valuable source of guidance and direction for companies and individuals interested in the market. Table of Contents 1 Industry Overview 1.1 Definition and Specifications of Cervical Cancer Drug 1.2 Classification of Cervical Cancer Drug 1.3 Applications of Cervical Cancer Drug 1.4 Industry Chain Structure of Cervical Cancer Drug 1.5 Industry Regional Overview of Cervical Cancer Drug 2 Manufacturing Cost Structure Analysis of Cervical Cancer Drug 2.1 Raw Material Suppliers and Price Analysis of Cervical Cancer Drug 2.2 Equipment Suppliers and Price Analysis of Cervical Cancer Drug 2.3 Labor Cost Analysis of Cervical Cancer Drug 2.4 Other Costs Analysis of Cervical Cancer Drug 3 Technical Data and Manufacturing Plants Analysis 3.1 Capacity and Commercial Production Date of Global Key Manufacturers in 2014 3.2 Manufacturing Plants Distribution of Global Key Cervical Cancer Drug Manufacturers in 2014 3.3 R&D Status and Technology Source of Global Cervical Cancer Drug Key Manufacturers in 2014 3.4 Raw Materials Sources Analysis of Global Cervical Cancer Drug Key Manufacturers in 2014 4 Production Analysis of Cervical Cancer Drug by Regions, Technology, and Applications 4.1 Global Production of Cervical Cancer Drug by Regions (US, EU, China, Japan, etc.) 2010-2015 4.2 Global Production of Cervical Cancer Drug by Technology 2010-2015 4.3 Global Production of Cervical Cancer Drug by Applications 2010-2015 4.4 Price Analysis of Global Cervical Cancer Drug Key Manufacturers in 2015 5 Sales and Revenue Analysis of Cervical Cancer Drug by Regions 5.1 Global Sales of Cervical Cancer Drug by Regions (US, EU, China, Japan, etc.) 2010-2015 5.2 Global Revenue of Cervical Cancer Drug by Regions (US, EU, China, Japan, etc.) 2010-2015 5.3 Global Price Analysis of Cervical Cancer Drug Sales by Regions (US, EU, China, Japan, etc.) 2010-2015 5.4 Global Price, Cost and Gross of Cervical Cancer Drug 2010-2015 6 Analysis of Cervical Cancer Drug Production, Supply, Sales and Market Status 2010-2015 6.1 Capacity and Production of Cervical Cancer Drug 2010-2015 6.2 Production Market Share Analysis of Cervical Cancer Drug 2010-2015 6.3 Sales Overview of Cervical Cancer Drug 2010-2015 6.4 Supply, Sales and Shortage of Cervical Cancer Drug 2010-2015 Enquire about report: http://www.bigmarketresearch.com/report-enquiry/300004
Просмотров: 43 Moira Warren
Bill Ackman: There's a Lot of Misinformation on Drug Pricing
 
03:52
Oct. 6 -- Activist investor Bill Ackman talks drug pricing and the controversy around Valeant Pharmaceuticals during an interview at the Bloomberg Markets Most Influential Summit. --Subscribe to Bloomberg on YouTube: http://www.youtube.com/Bloomberg
Просмотров: 10485 Bloomberg
As first female libido drug hits the market, more options in
 
00:33
YOUR DESCRIPTION HAS REACHED THE LIMIT OF CHARACTERS ALLOWED AND WAS CUT. WASHINGTON (CBS NEWS) -- Most women with low sexual desire won't rush to get the first prescription drug to boost female libido when it becomes available on Saturday. But they may have more options down the road. Addyi is a daily medication that can't be taken with alcohol or certain other drugs, which will likely limit its use. But experts believe those restrictions could spur development of better treatments for women's sexual problems after more than a decade of neglect by most of the world's large drugmakers. Kim Wallen, a psychology professor at Emory University, says Addyi represents a historic milestone that may open the door to more drugs targeting desire in men and women. Where Viagra and other men's erectile dysfunction drugs work by increasing blood flow to the genitals, Addyi acts on brain chemicals associated with desire. "This is the first time that a drug, for either men or women, has been approved strictly to increase sexual desire," Wallen says. "That legitimizes many other drugs that are in development." Treatments for women's libido issues are an untapped financial opportunity for drugmakers. Analysts estimate the market could be worth over billion, based on academic estimates that between 5 million and 9 million U.S. women may suffer from desire disorders. But the area hasn't been a research priority for drugmakers in many years. Beginning in the 1990s, Pfizer, Bayer and Procter Gamble all studied - then discarded - drugs targeting female libido. Addyi itself was developed by the German conglomerate, Boehringer Ingelheim, then sold to Sprout Pharmaceuticals after the Food and Drug Administration rejected the medication due to lackluster effectiveness and issues like nausea, fatigue and dizziness. It took Sprout four years to win FDA approval for Addyi, which was finally granted in August, on the third try. "They really struggled with this, even agonized over the decision," said CBS News chief medical correspondent Dr. Jon LaPook. "Because they said the benefits were kind of modest and there were some significant side effects they were worried about: dizziness, sleepiness, and when used with alcohol, fainting." The drug, which acts on brain chemicals associated with mood and appetite, will come with a bold warning label about the risks of fainting if combined with alcohol or certain medications. Additionally, doctors and pharmacists must complete an online certification process to show they understand the drug's risks. Dr. Lisa Dabney says several patients have asked her about Addyi, but they generally lose interest after she explains they cannot drink alcohol while taking the daily medication. "It's definitely an option that's going to help patients," says Dabney, of New York's Mt. Sinai hospital. "But it's going to have a limited patient audience because of the alcohol restrictions and the fact that you have to take it every day." Still, some women credit the drug with saving their relationships. Amanda Parrish, 52, had been married for three years when she realized she was avoiding sex with her husband. Her doctor said it was natural to lose sexual interest with age and suggested she try a vibrator. But nothing worked until Parrish enrolled in a trial of Addyi, which was studied in women who report distress due to a lack of libido. "It just brought me back to where I was as far as being flirty and playful," says Parrish, who lives in Nashville. "I went back to the days of leaving notes on his window, in his car, on his mirror in the morning." Sheri Mike, a 34-year-old mother of two, told CBS News she hopes it will make a difference for her. "I've tried vitamins, me and my husband have tried counseling, I've tried hypnotherapy, but none of those have worked," she said."The lack of desire, the lack of sexual thoughts, no libido -- it's just this one area that's kind of holding us back from being truly happy." Experts generally describe Addyi's effect as "modest." In company studies, women taking the drug that's also called flibanserin reported a slight uptick in sexually satisfying events each month. Their answers to separate questionnaires indicated they experienced a slight increase in desire and a slight decrease in stress. Analysts from Evercore ISI estimate Addyi could generate sales of 00 million annually. That's far below the blockbuster numbers once discussed by experts and the billion that Valeant Pharmaceuticals recently agreed to purchase Sprout. But the buyout has revived interest in a handful of competitors developing alternate treatments. Those products include nasal sprays, injections and antidepressant pills. It could be years before any of them reach patients. That's because the field of women's sexual medicine remains a small one, comprised of tiny companies with limited resources. Leading the field is Cranbury, N.J.-based Palatin Technologies Inc. which is studying an injectable
Просмотров: 458 LOCAL 12
Pfizer/Allergan – the numbers | Lex
 
02:17
► Subscribe to the Financial Times on YouTube: http://bit.ly/FTimeSubs Botox maker Allergan is in discussions about selling itself to Pfizer, a deal that would create the world’s largest drugmaker. Lex's Robert Armstrong picks apart the details. For more video content from the Financial Times, visit http://www.FT.com/video Twitter https://twitter.com/ftvideo Facebook https://www.facebook.com/financialtimes
Просмотров: 867 Financial Times
Antidepressant Market in the US 2015 2019
 
00:56
Antidepressant Market in the US 2015 2019 http://www.marketresearchstore.com/report/antidepressant-market-in-the-us-2015-2019-4322 According to the WHO, depression is a common mental disorder which contributes significantly to the global burden of disease. It affects people across communities in the world. It is characterized by sadness, loss of interest or pleasure, feelings of guilt or low self-worth, disturbed sleep or appetite, feelings of tiredness, and poor concentration, as stated by the WHO. Depression can roughly be categorized into six different types. A patient with severe depression can have suicidal thoughts or behaviors. According to a 2012 WHO estimate, approximately 3,000 suicides take place each day, resulting in more than a million deaths per annum. Table of Content 1. Executive Summary 2. List of Abbreviations 3. Scope of the Report 3.1 Market Overview 3.2 Product Offerings 4. Product Profiles 4.1.1 Celexa 4.1.2 Fetzima 4.1.3 Lexapro 4.1.4 Viibryd 4.1.5 Cymbalta 4.1.6 Prozac 4.1.7 Symbyax 4.1.8 Paxil 4.1.9 Wellbutrin 4.1.1 Abilify 4.1.11 Effexor 4.1.12 Pristiq 4.1.13 Zoloft 5. Market Research Methodology 5.1 Market Research Process 5.2 Research Methodology 6. Introduction 7. Disorder Overview 7.1 Depression & its Types 7.1.1 Major Depressive Disorder 7.1.2 Persistent Depressive Disorder 7.1.3 Psychotic Depression 7.1.4 Post-partum Depression 7.1.5 Seasonal Affective Disorder 7.1.6 Bipolar Disorder 7.2 Etiology 7.3 Epidemiology 7.3.1 Bipolar Disorder Among Adults 7.3.2 Dysthymic Disorder Among Adults 7.3.3 Major Depression Among Adults 7.3.4 Major Depression Among Adolescents 7.4 Treatment & Management 7.5 Economic Burden 8. Market Landscape 8.1 Market Overview 8.2 Market Size and Forecast 8.3 Five Forces Analysis 9. Market Segmentation by Mechanism of Action 10. Buying Criteria 11. Market Growth Drivers 12. Drivers and their Impact 13. Market Challenges 14. Impact of Drivers and Challenges 15. Market Trends 16. Trends and their Impact 17. Vendor Landscape 17.1 Competitive Scenario 17.1.1 Key News 17.1.2 Mergers and Acquisitions 17.2 Market Share Analysis 2014 17.2.1 Competitive Assessment of the Top Drugs for Depression 17.2.2 Eli Lilly 17.2.3 Otsuka Pharmaceutical 17.2.4 Pfizer 17.2.5 GlaxoSmithKline 17.2.6 Actavis 17.3 Other Prominent Vendors 18. Key Vendor Analysis 18.1 Actavis 18.1.1 Key Facts 18.1.2 Business Description 18.1.3 Business Segmentation 18.1.4 Business Segmentation by Revenue 2012 and 2013 18.1.5 Sales by Geography 18.1.6 Business Strategy 18.1.7 Key Information 18.1.8 SWOT Analysis 18.2 Eli Lilly 18.2.1 Key Facts 18.2.2 Business Overview 18.2.3 Business Segmentation by Revenue 18.2.4 Sales by Geography 18.2.5 Business Strategy 18.2.6 Key Information 18.2.7 SWOT Analysis 18.3 GlaxoSmithKline 18.3.1 Key Facts 18.3.2 Business Overview 18.3.3 Business Segmentation 18.3.4 Business Segmentation by Revenue 2012 and 2013 18.3.5 Sales by Geography 18.3.6 Pipeline Products 18.3.7 Business Strategy 18.3.8 Key Information 18.3.9 SWOT Analysis 18.4 Otsuka Pharmaceutical 18.4.1 Key Facts 18.4.2 Business Overview 18.4.3 Business Segmentation by Revenue 2014 18.4.4 Business Segmentation by Revenue 2013 and 2014 18.4.5 Geographical Segmentation by Revenue 2014 18.4.6 Business Strategy 18.4.7 Recent Developments 18.4.8 SWOT Analysis 18.5 Pfizer 18.5.1 Key Facts 18.5.2 Business Overview 18.5.3 Business Segmentation by Revenue 2013 18.5.4 Business Segmentation by Revenue 2012 and 2013 18.5.5 Geographical Segmentation by Revenue 18.5.6 Business Strategy 18.5.7 Key Developments 18.5.8 SWOT Analysis
Просмотров: 146 Market Research Store
Police Put Big Pharma CEOs On Blast
 
07:47
The police department in Gloucester, Massachusetts has decided to take a completely different strategy in combating the war on drugs. They are posting the contact information of the top five pharmaceutical CEOs. They are urging citizens to politely call the offices of these CEOs to inform them that their drugs are the ones people are getting hooked on, and asking what they’re doing to combat addiction. Cenk Uygur, Ana Kasparian (The Point), Jaclyn Glenn (JaclynGlenn), and Jimmy Dore (The Jimmy Dore Show) hosts of The Young Turks discuss. Do you support the police departments efforts? Should more departments make this move? Let us know in the comments below. Read more here: http://www.boston.com/news/2015/09/17/gloucester-police-post-names-salaries-and-contact-info-big-pharma-ceos/LK5jP65QoZc8DXwI7kFRxO/story.html?p1=Must_Reads_hp “The Gloucester Police Department continued its fight against opiate addiction on Wednesday with yet another unusual tactic. In a post on the department’s Facebook page, Gloucester police posted the names, salaries, and contact information for five of the highest paid CEOs of pharmaceutical companies and urged readers to make some calls.” ********** The Young Turks September 18, 2015 Hour 2 https://www.youtube.com/playlist?list=PLTpcK80irdQg6IWue9zX4NPwUJBkHAstI Trump Fans Are So Sick Of Hearing This... https://www.youtube.com/watch?v=L9P4LDGXOmQ&list=PLTpcK80irdQg6IWue9zX4NPwUJBkHAstI&index=1 Bristol Palin Thinks Ahmed Mohamed White House Visit Demonizes Cops https://www.youtube.com/watch?v=JVrR8hnmZvE&list=PLTpcK80irdQg6IWue9zX4NPwUJBkHAstI&index=2 Waitresses Can Now Be Fired If They Gain Weight https://www.youtube.com/watch?v=7hUkxn66CyY&list=PLTpcK80irdQg6IWue9zX4NPwUJBkHAstI&index=3 Police Put Big Pharma CEOs On Blast https://www.youtube.com/watch?v=SJW1A-tja7U&list=PLTpcK80irdQg6IWue9zX4NPwUJBkHAstI&index=4 ********** The Largest Online News Show in the World. Hosted by Cenk Uygur and Ana Kasparian. LIVE STREAMING weekdays 6-8pm ET. Young Turk (n), 1. Young progressive or insurgent member of an institution, movement, or political party. 2. Young person who rebels against authority or societal expectations. (American Heritage Dictionary) ********** Get The Young Turks​ Mobile App Today! Download the iOS version here: https://itunes.apple.com/us/app/the-young-turks/id412793195?ls=1&mt=8 Download the Android version here: https://play.google.com/store/apps/details?id=com.tyt
Просмотров: 87191 The Young Turks
Blue Promise: Specialty Pharmaceuticals
 
04:55
$500,000/year for one medication? It sounds outrageous, but specialty pharmaceuticals can also have unbelievably positive life changing benefits. So if we’re trying to manage health care costs, how do we determine when they should be used? In this episode of Blue Promise, Dr. McCoy and Dr. Paul Hain weigh the pros and cons of specialty drugs. Blue Promise is an online video blog that aims to address complicated health issues with candid conversations from subject matter experts. New editions are published regularly and are hosted by Dr. Dan McCoy, Blue Cross and Blue Shield of Texas' Chief Medical Officer and Divisional Senior Vice President of Texas Market Strategy
Просмотров: 341 Blue Cross and Blue Shield of Texas
Dr. Nicholas Ibogaine Treatment Testimonial | Discusses Suboxone, Adderall & U.S. Lobbying
 
07:50
Ibogaine by David Dardashti www.ibogaineclinic.com Dr. Nicholas shares his personal story with an ibogaine detox treatment as David Dardashti from, founder of ibogaineclinic.com interviews him. In this video, Dr. Nicholas talks about the pressures of going to med school, his adderall addiction (amphetamine) and being in a very dark place. He’s tried conventional American rehab centers, and says all he was left with is a near-death experience and a bunch of anti-depressants from psychiatrists. Dr. Nicholas also explains why ibogaine treatment centers are illegal in the U.S. and that is because the biggest lobbyists in the U.S. are the pharmaceutical companies. If they were to legalize an ibogaine treatment, they would lose too much money because they’re the ones pushing the suboxone, methadone and more. In his testimonial, Dr. Nicholas goes on to say that there’s a lot of scientific research supporting the success of an ibogaine treatment for addiction as well as other diseases. For example, Columbia University has research to support an ibogaine treatment can reverse Parkinson’s. An ibogaine treatment program can also help to fight Alzheimer’s. But he says, the statistics and research done by David Dardashti at Ibogaine Clinic is far more advanced that what he’s seen in his own medical circles, that’s why he entered the this one instead of the several ibogaine rehab centers. Dr. Nicholas talks about Suboxone, how you can be a slave to it, but he guarantees you’ll feel better after an ibogaine treatment versus Suboxone. Keep watching to see how Dr. Nicholas went from being skeptical to truly believing in the power of an ibogaine treatment, helping his own body to fix itself. For more information, call the Ibogaine Clinic at 1.866.462.1164 or visit IbogaineClinic.com. We thank Dr. Nicholas for his testimonial. Instagram: https://www.instagram.com/ibogainedaviddardashti/ Facebook: https://www.facebook.com/Ibogaineclinic Tumblr: http://ibogainebydavid.tumblr.com/ Twitter: https://twitter.com/ibogainedavidd
Просмотров: 782 Ibogaine By David Dardashti
HireLifeScience.com - Pharmaceutical, Biotechnology, Medical Device and Life Science Careers
 
00:47
If you are searching for microbiology jobs, regulatory affairs jobs, analytical chemistry jobs, pharmacology jobs or anything in between; you can connect directly with employers through HireLifeScience.com!
Просмотров: 62 Hirelifescience LLC
Has Drugs been suppressed by the pharmaceutical companies?
 
04:25
This video gives a brief explanation of the supposed suppression of drugs by the pharmaceutical companies and explains the conspiracy behind this phenomenon.
Просмотров: 125 Sinister Conspiracies
Yelawolf - American You
 
03:38
Pre-order the album Love Story now On iTunes: http://smarturl.it/YelaLoveStory Google Play: http://smarturl.it/YelaLoveStoryGP Amazon MP3: http://smarturl.it/YelaLoveStoryAmz Sign up for updates: http://smarturl.it/Yelawolf.News Best of Yelawolf: https://goo.gl/vy7NZQ Subscribe here: https://goo.gl/ynkVDL
Просмотров: 32889465 YelawolfVEVO
AppExchange for Life Sciences: Where Cloud Meets Compliance
 
38:30
The Life Sciences industry has unique needs and requirements, from Global Regulatory Compliance to Clinical Trial Management, from Quality Manufacturing to Device Tracking, and more! Join us to learn why partners are choosing the Salesforce1 platform to develop apps for Life Sciences and how customers are succeeding using those apps. We'll share apps that have been built specifically to address the needs of medical devices and pharmaceutical organizations, as well as apps that make your users more productive. You'll walk away with real-world knowledge of how to further your investments in Salesforce technologies.
Просмотров: 524 Dreamforce Video
Aventis, Sanofi bosses meet for direct talks
 
03:34
1. Various of Aventis headquarters in Paris 2. Various of Sanofi-Synthelabo headquarters in Paris 3. Exterior of building 4. Various of Florent Cespedes, European Pharmaceuticals Equity Analyst for Natexis Bleichroeder 5. SOUNDBITE (English) Florent Cespedes, European Pharmaceuticals Equity Analyst for Natexis Bleichroeder: "If a merger between Sanofi-Synthelabo and Aventis makes sense we believe that a merger between Novartis and Aventis makes more sense than ever because there is a very good fit in terms of product portfolio, R''n''D (Research and Development) portfolio between both groups and Novartis may benefit for example from the very strong diabetes franchise of Aventis with this portfolio. So it could be a very good reason to merge both groups." 6. Cutaway 7. SOUNDBITE (English) Florent Cespedes, European Pharmaceuticals Equity Analyst for Natexis Bleichroeder: "There are two conditions for Novartis to make an offer. The first one is an invitation from the Aventis supervisory board. This is already done. The second step is that the French government must remain neutral. For the time being it''s not very clear, the situation of the French government. But according to the press release of Novartis yesterday following its first quarter numbers, it seems that Novartis is making another step towards an offer. So we can assume that Novartis believes that the French government will remain neutral." 8. Various cutaways 9. SOUNDBITE (English) Florent Cespedes, European Pharmaceuticals Equity Analyst for Natexis Bleichroeder: "This is a strategical move for Aventis and Novartis. It is not only something tactical just to put pressure on Snafu to increase its offer. It''s really if Novartis makes its offer it''s to succeed and not only to put pressure on Sanofi." 10. Close shot of chemist sign 11. Wide shot of chemist 12. Medium interior shot of chemist 13. Various of Aventis/Sanofi-Synthelabo/Novartis medicines 14. Wide interior shot of chemist STORYLINE: France''s market watchdog said on Friday that a planned warrant issue by drug maker Aventis SA breaks market rules, dealing a blow to its attempts to fend off a hostile bid from smaller rival Sanofi-Synthelabo SA. In a statement, the Financial Markets Authority said the planned issue "does not conform to the principles that govern public offers." The decision, which is not binding but is likely to carry considerable weight with Aventis shareholders, undermines efforts by the Strasbourg-based company to resist Sanofi''s advances and negotiate a merger with Switzerland''s Novartis AG. It comes a day after Novartis said it has accepted Aventis'' invitation to enter into friendly merger talks, but stressed that "no assurances can be given that an agreement will be reached." Aventis had announced plans to distribute warrants to shareholders which would allow them to buy new shares at a knockdown price if Sanofi wins control of Aventis but loses a US patent challenge against Plavix, Sanofi''s best selling drug. The move was ostensibly designed to protect Aventis shareholders against the Plavix risk by handing them a bigger portion of the merged company if generic copies of the blood thinner are allowed onto the US market. But it was also widely seen as a "poison pill" intended to thwart or at least set back Sanofi''s offer and buy enough time for merger talks with Novartis to lead to a friendly deal. Poison pills are a defensive tactic usually used against hostile bidders in a takeover battle. Earlier on Friday, at the request of French Finance Minister Nicolas Sarkozy, the heads of Sanofi and Aventis held their first direct talks since Sanofi announced its hostile bid on January 26. You can license this story through AP Archive: http://www.aparchive.com/metadata/youtube/d4478e5840b293a2b05304e167a1d90d Find out more about AP Archive: http://www.aparchive.com/HowWeWork
Просмотров: 275 AP Archive
Newsworthy Numbers - Part 1
 
01:02
British researchers found that study participants with Vitamin D levels below 50 nanomoles per liter, the minimum healthy level, were up to two times more likely to suffer from dementia than those with higher levels. $7.9 billion is the amount of money spent last year on Sovaldi, a treatment for hepatitis C and the prescription drug with the highest U.S. sales. Last year, spending on prescription drugs reached $374 billion. That’s up 13% from 2013 according to a study by the IMS Institute for Healthcare Informatics. 270 servings per person per year, that’s the volume of single-serve, unflavored bottled water in the U.S. marketplace.
Просмотров: 13 HometownHealth
Apotex International - An Overview
 
06:18
Apotex believes that every man, woman and child is entitled to affordable medical care and freedom from pain and suffering. For close to 40 years, Apotex has met the healthcare challenges of tomorrow and fought hard to build a successful worldwide pharmaceutical company. Through a strategy of vertical integration, Apotex has built an exceptional scientific and manufacturing base that supports a global sales and marketing infrastructure. We have done this on the heels of our continued commitment to excellence. Apotex is focused on meeting the world’s need for the highest quality, affordable medicines. We have built the facilities, the scientific R&D base, and the technology to meet the healthcare needs of the world for today and tomorrow. With an established network of international affiliates and distributors, our medicines are present in more than 115 countries.
Просмотров: 3540 Apotex Inc.
TPP’s Biggest Winner: Big Pharma - The Ring Of Fire
 
10:46
Now that Fast Track has passed the hurdles of Congress, President Obama is absolutely giddy with excitement that his TPP trade deal might finally be happening. The best economists tell us that we’ll lose more jobs from this deal than we did from NAFTA and CAFTA, but that hasn’t stopped the President from telling us that this is the most progressive trade deal in history. The little information that has been leaked about the TPP tells us that the only groups to benefit will be corporations, specifically the drug industry. America’s Lawyer, Mike Papantonio, and attorney Howard Nations talk about that. Spread the word! LIKE and SHARE this video or leave a comment to help direct attention to the stories that matter. And SUBSCRIBE to stay connected with Ring of Fire's video content! Listen to Ring of Fire on Saturdays from 3pm - 6pm Eastern! Listen live via the Progressive Voices Channel on TuneIn: http://tunein.com/radio/Progressive-Voices-s189055/ Or find a station here: http://www.ringoffireradio.com/station/ Watch Ring of Fire every weekday at 8:30pm EST on Free Speech TV! Support Ring of Fire by subscribing to our YouTube channel: http://www.youtube.com/user/golefttv You can also support us here: http://www.ringoffireradio.com/support/ Your continued support keeps Ring of Fire on the air! Follow more of our stories at http://www.RingofFireRadio.com Be sociable! Follow us on: Facebook: http://www.facebook.com/RingofFireRadio Twitter: http://www.twitter.com/RingofFireRadio Google+: http://plus.google.com/118415831573195648557 Support us further by shopping on Amazon via our Amazon-Ring of Fire partnership link. A portion of the sales will come back to Ring of Fire at no extra cost to you. Bookmark and follow the link below and continue shopping as usual! Amazon - Ring of Fire partnership link: http://www.amazon.com/?tag=rinoffir-20
Просмотров: 898 The Ring of Fire
Global Disposable Medical Gloves Industry 2015 Deep Market Research Report
 
00:31
Big Market Research “Global Disposable Medical Gloves Industry” Size, Share, Industry Trends, Demand, Insights, Analysis, Research, Report, Opportunities, Company Profiles, Forecast to 2020. The Global Disposable Medical Gloves Industry 2015 Deep Market Research Report is a professional and in-depth study on the current state of the Disposable Medical Gloves industry. The report provides a basic overview of the industry including definitions, classifications, applications and industry chain structure.The Disposable Medical Gloves market analysis is provided for the international markets including development trends, competitive landscape analysis, and key regions development status. Development policies and plans are discussed as well as manufacturing processes and cost structures are also analyzed. This report also states import/export consumption, supply and demand Figures, cost, price, revenue and gross margins. Read more details at: http://www.bigmarketresearch.com/global-disposable-medical-gloves-industry-2015-deep-research-report-market The Global Disposable Medical Gloves Industry, report focuses on global major leading industry players providing information such as company profiles, product picture and specification, capacity, production, price, cost, revenue and contact information. Upstream raw materials and equipment and downstream demand analysis is also carried out. The Disposable Medical Gloves industry development trends and marketing channels are analyzed. Finally the feasibility of new investment projects are assessed and overall research conclusions offered. With 165 tables and figures the report provides key statistics on the state of the industry and is a valuable source of guidance and direction for companies and individuals interested in the market. Table of Contents 1 Industry Overview 1.1 Definition and Specifications of Disposable Medical Gloves 1.2 Classification of Disposable Medical Gloves 1.3 Applications of Disposable Medical Gloves 1.4 Industry Chain Structure of Disposable Medical Gloves 2 Manufacturing Cost Structure Analysis of Disposable Medical Gloves 2.1 Raw Material Suppliers and Price Analysis of Disposable Medical Gloves 2.2 Equipment Suppliers and Price Analysis of Disposable Medical Gloves 2.3 Labor Cost Analysis of Disposable Medical Gloves 2.4 Other Costs Analysis of Disposable Medical Gloves 3 Technical Data and Manufacturing Plants Analysis 3.1 Capacity and Commercial Production Date of Global Key Manufacturers in 2014 3.2 Manufacturing Plants Distribution of Global Key Disposable Medical Gloves Manufacturers in 2014 3.3 R&D Status and Technology Source of Global Disposable Medical Gloves Key Manufacturers in 2014 3.4 Raw Materials Sources Analysis of Global Disposable Medical Gloves Key Manufacturers in 2014 4 Production Analysis of Disposable Medical Gloves by Regions, Technology, and Applications 4.1 Global Production of Disposable Medical Gloves by Regions (US, EU, China, Japan, etc.) 2010-2015 4.2 Global Production of Disposable Medical Gloves by Technology 2010-2015 4.3 Global Production of "& B1 &" by Applications 2010-2015 4.4 Price Analysis of Global Disposable Medical Gloves Key Manufacturers in 2015 5 Sales and Revenue Analysis of Disposable Medical Gloves by Regions 5.1 Global Sales of Disposable Medical Gloves by Regions (US, EU, China, Japan, etc.) 2010-2015 5.2 Global Revenue of Disposable Medical Gloves by Regions (US, EU, China, Japan, etc.) 2010-2015 5.3 Global Price Analysis of Disposable Medical Gloves Sales by Regions (US, EU, China, Japan, etc.) 2010-2015 5.4 Global Price, Cost and Gross of Disposable Medical Gloves 2010-2015 6 Analysis of Disposable Medical Gloves Production, Supply, Sales and Market Status 2010-2015 6.1 Capacity and Production of Disposable Medical Gloves 2010-2015 6.2 Production Market Share Analysis of Disposable Medical Gloves 2010-2015 6.3 Sales Overview of Disposable Medical Gloves 2010-2015 6.4 Supply, Sales and Shortage of Disposable Medical Gloves 2010-2015 Enquire About Report: http://www.bigmarketresearch.com/report-enquiry/300690
Просмотров: 151 Melvin Wells
Free Speech TV | Episode 193 - Saving The American Middle Class - The Ring Of Fire
 
29:00
The Republican Party’s Civil War has hit a new high, or low depending on how you look at it – and we’ll tell you all about it… Democratic Presidential candidates keep talking about the need for a stronger middle class, but we haven’t heard anyone talking about where the middle class actually went. We’ll give you the history tonight… And we’ll give you the details about a whistleblower lawsuit that recently made our roadways a lot safer… Follow more of our stories at http://www.RingofFireRadio.com Spread the word! LIKE and SHARE this video or leave a comment to help direct attention to the stories that matter. And SUBSCRIBE to stay connected with Ring of Fire's video content! Listen to Ring of Fire on Saturdays from 3pm - 6pm Eastern! Listen live via the Progressive Voices Channel on TuneIn: http://tunein.com/radio/Progressive-Voices-s189055/ Or find a station here: http://www.ringoffireradio.com/station/ Watch Ring of Fire every weekday at 8:30pm EST on Free Speech TV! Support Ring of Fire by subscribing to our YouTube channel: http://www.youtube.com/user/golefttv You can also support us here: http://www.ringoffireradio.com/support/ Your continued support keeps Ring of Fire on the air! Be sociable! Follow us on: Facebook: http://www.facebook.com/RingofFireRadio Twitter: http://www.twitter.com/RingofFireRadio Google+: http://plus.google.com/118415831573195648557 Support us further by shopping on Amazon via our Amazon-Ring of Fire partnership link. A portion of the sales will come back to Ring of Fire at no extra cost to you. Bookmark and follow the link below and continue shopping as usual! Amazon - Ring of Fire partnership link: http://www.amazon.com/?tag=rinoffir-20
Просмотров: 1251 The Ring of Fire
Lupin Q4 Net Profit Slips; Slow Growth Dents Margins: Interview with CEO, Nilesh Gupta
 
13:39
Drug firm Lupin saw consolidated net profit fell 1.1 percent to Rs 547 crore in January-March quarter from Rs 553 crore in the corresponding quarter last fiscal. During the period, its revenue was alm
Просмотров: 402 CNBC-TV18
Price control for medical devices planned | India | News7 Tamil |
 
03:37
NEWS7 TAMIL Central Government of India plans to issue price control order for medical devices.It is expected that medical devices sold in the Indian market could drop by as much as 50 percent from current prices. http://www.NS7.tv facebook: http://fb.com/News7Tamil twitter: http://twitter.com/News7Tamil News 7 Tamil Television, part of Alliance Broadcasting Private Limited, is rapidly growing into a most watched and most respected news channel both in India as well as among the Tamil global diaspora. The channel’s strength has been its in-depth coverage coupled with the quality of international television production.
Просмотров: 42 News7 Tamil
Johnson & Johnson Pharma Division Provides Earnings Bright Spot
 
00:51
Johnson and Johnson (JNJ) posted earnings on Tuesday that topped Wall Street estimates. The health and personal care giant faced currency headwinds due to the strong dollar but has increased its outlook for 2015, boosting guidance to $6.10-$6.20 per share for the year, up from $6.04-$6.19 per share. The company reported profits of $1.71 per share, up from last year's numbers and beating Wall Street estimates. Revenue was down almost 9 percent from $19.5 billion to $17.8 billion but topped estimates. The brand has topped estimates for the last 17 quarters in a run of over four years. The company's pharmaceutical division was a bright spot. Sales of its arthritis drug Simponi jumped 30 percent in the U.S. market. Johnson and Johnson also announced last month that it had received FDA approval for a new schizophrenia treatment which only needs to be administered four times a year, giving patients greater independence from their dosing. Johnson and Johnson shares have dropped almost 4 percent in the last year. Subscribe to TheStreetTV on YouTube: http://t.st/TheStreetTV For more content from TheStreet visit: http://thestreet.com Check out all our videos: http://youtube.com/user/TheStreetTV Follow TheStreet on Twitter: http://twitter.com/thestreet Like TheStreet on Facebook: http://facebook.com/TheStreet Follow TheStreet on LinkedIn: http://linkedin.com/company/theStreet Follow TheStreet on Google+: http://plus.google.com/+TheStreet
Просмотров: 155 TheStreet: Investing Strategies
Closing Bell: Stocks Slide as Biotech Sells Off
 
01:17
Stocks suffered losses Wednesday as the biotech sector sold off. Boeing (BA) helped to minimize the Dow's fall after a better-than-expected third quarter. Valeant Pharmaceuticals (VRX) recovered from losses of more than 40% after the company defended its accounting practices. Short-seller Citron Research had accused the drugmaker of fudging sales numbers. Billionaire investor Bill Ackman also disclosed that he had purchased an additional two million shares during the selloff. KLA-Tencor (KLAC) jumped after larger rival Lam Research (LRCX) agreed to buy the chipmaker for nearly $11 billion. The deal is the latest in a sector coping with slowing growth and increasing expenses. Subscribe to TheStreetTV on YouTube: http://t.st/TheStreetTV For more content from TheStreet visit: http://thestreet.com Check out all our videos: http://youtube.com/user/TheStreetTV Follow TheStreet on Twitter: http://twitter.com/thestreet Like TheStreet on Facebook: http://facebook.com/TheStreet Follow TheStreet on LinkedIn: http://linkedin.com/company/theStreet Follow TheStreet on Google+: http://plus.google.com/+TheStreet
Просмотров: 143 TheStreet: Investing Strategies
RANBAXY LABORATORIES LTD - Recruitment Notification 2017– Jobs,Openings,Exam dates & results
 
03:41
Latest RANBAXY LABORATORIES LTD Recruitment Notification 2017. Apply today for Jobs & Careers at RANBAXY LABORATORIES LTD – Trainee jobs,The Govt jobs and Employment News channel from Freshersworld.com – The No.1 job portal for freshers in India. Visit http://www.freshersworld.com/ranbaxy-laboratories-jobs-careers/4444191?src=Youtube for detailed job information, recruitment notification, eligibility criteria, application form, general dates, exam results of RANBAXY LABORATORIES LTD. Ranbaxy Laboratories Ltd is a multinational pharmaceutical company that is based in India. The company spends its maximum resources on research and development department. Thus, the number of candidates being selected in R&D is higher than other departments. When it comes to research, the candidates with master degree and doctoral in various fields of medical sciences are usually preferred. Doctors with MD degree are chosen for researcher field. Candidates with doctoral in biotechnology, pharmaceutical or other allied fields are chosen as research assistant. Candidates with master degree in chemistry, biotechnology and other departments are chosen for research associate positions. The Ranbaxy Laboratories limited recruitment happens through campus drive and also through direct recruitment process. The candidates can apply for the positions through the official site. Not just science candidates, the candidates from varying fields like engineering to management are chosen for various departments starting from sales to general administration. When it comes to selection process of Ranbaxy jobs, the candidates have to take up a technical written test, group discussion and personal interview. The written test’s scope, pattern and syllabus would vary based on the educational requirement and type of job profile. The group discussion round would involve a general topic where the communication skills and interpersonal skills of the candidates would be tested. The written test for pharma jobs would not be the same as that of the test for management executives. The group discussion and the other levels would be common for almost all the positions. But, the importance given to each level would vary. When it comes to research and development department, the group discussion would not be of higher value when compared to the sales team recruitment process. .Visit Preparation and placement tips for RANBAXY LABORATORIES LTD jobs at : http://placement.freshersworld.com?src=Youtube For more jobs & career information and daily job alerts, subscribe to our channel and support us. You can also install our Mobile app for govt jobs for getting regular notifications on your mobile. Freshersworld.com is the No.1 job portal for freshers jobs in India. Check Out website for more Jobs & Careers. http://www.freshersworld.com?src=Youtube - - ***Disclaimer: This is just a career guidance video for fresher candidates. The name, logo and properties mentioned in the video are proprietary property of the respective companies. The career and job information mentioned are an indicative generalised information. In no way Freshersworld.com, indulges into direct or indirect recruitment process of the respective companies.
Просмотров: 30661 Freshersworld.com Jobs & Careers
FDA Gives Pfizer Nod for Breast Cancer Drug Two Months Early
 
02:55
Disney, Macy's and Green Mountain Coffee Roasters are in focus in earnings news and Pfizer gets the greenlight from the FDA for a breast cancer drug two months early. Disney posted better than expected earnings and higher revenue in its latest quarter thanks to strong topline numbers from its TV networks and sales of paraphernalia associated with the animated movie Frozen. Macy's is a stock to watch today as it raised its outlook for the year and plans to buy BlueMercury for $210 million in cash. The FDA has granted early approval of Pfizer's drug used to treat advanced stage breast cancer. The approval of Inbrance came two months early. Pfizer needs some big-selling new drugs to boost its earnings, following patent expirations on many of its biggest brands and a relatively thin supply of promising drugs in late-stage trials. Pfizer said the drug is available to order immediately through specialty pharmacies. Keurig Green Mountain Coffee Roasters turns in first quarter earnings results today. KeyBank Capital Markets reiterates its BUY rating on GMCR with a $175 price target. Sales of single K Cups versus sales of brewers are expected to drive numbers. Subscribe to TheStreetTV on YouTube: http://t.st/TheStreetTV For more content from TheStreet visit: http://thestreet.com Check out all our videos: http://youtube.com/user/TheStreetTV Follow TheStreet on Twitter: http://twitter.com/thestreet Like TheStreet on Facebook: http://facebook.com/TheStreet Follow TheStreet on LinkedIn: http://linkedin.com/company/theStreet Follow TheStreet on Google+: http://plus.google.com/+TheStreet
Просмотров: 160 TheStreet: Investing Strategies
Sharp rise in Kids two or under given Psychiatric Drugs.
 
03:02
According to the National Center for Health Statistics, the rate of anti-depressant use has increased nearly 400 percent in the past two decades, but those statistics do not include the youngest group of patients being treated with psychiatric drugs. RT’s Marina Portnaya has details on the startling new trend of treating kids two years or under. Find RT America in your area: http://rt.com/where-to-watch/ Or watch us online: http://rt.com/on-air/rt-america-air/ Like us on Facebook http://www.facebook.com/RTAmerica Follow us on Twitter http://twitter.com/RT_America .
Просмотров: 139 The River Mersey
Analysis of the Expanding U.S. Market for Gastrointestinal Disorders Prescription Pharmaceuticals
 
01:13
1. Investigation of the Expanding U.S. Market for Gastrointestinal Disorders Prescription Pharmaceuticals Bowel Disorders Market is Buoyant and Poised for Growth NBB6-52 November 2012 2. ContentsSection Slide Numbers Executive Summary 14 Market Overview 20 • Definitions 21 • Overview of Inflammatory Bowel Disease 23 o Incidence and Prevalence of Inflammatory Bowel Disease 24 o Diagnosis of Inflammatory Bowel Disease 25 o Clinical Severity of Inflammatory Bowel Disease 27 o Assessment of Disease Activity in IBD Clinical Trials 29 o Anatomic Extent of Ulcerative Colitis 31 o Clinical Guidelines 33 • Overview of Irritable Bowel Syndrome 38 o Diagnosis of IBS 39 o Assessment of Disease Activity in IBS Clinical Trials 40 o Clinical Trial Design Guidance—IBS 41 o Clinical Guidelines—IBS 43 • Personalized Medicine in Bowel Disorders 44 • Key Questions This Study Will Answer 45 • Market Overview—Segmentation 46NBB6-52 3. Substance (continued)Section Slide Numbers External Challenges: Drivers and Restraints 57 Forecasts and Trends 69 Demand Analysis 84 Market Share and Competitive Analysis 87 Inflammatory Bowel Disease Prescription Pharmaceuticals Segment 123 •5-ASA Subsegment Breakdown 127 •Corticosteroid Subsegment Breakdown 138 •TNF Inhibitor Subsegment Breakdown 149 •Non-TNF Biologicals Subsegment Breakdown 160 •Novel Orals Subsegment Breakdown 169 Irritable Bowel Syndrome Prescription Pharmaceuticals Segment 177 The Last Word (Conclusions and Implications) 188 Game-changing Strategies 193 Appendix 195NBB6-52 4. Research TeamLead Analyst Contributing AnalystDeborah Toscano Jennifer BriceSenior Industry Analyst Global Program ManagerLife Sciences Life SciencesResearch Director Strategic Review Committee LeaderDaniel Ruppar Greg CaressiResearch Director Sr. Bad habit PresidentHealthcare HealthcareNBB6-52 5. Official Summary—CEO's Perspective Growth opportunity in the IBD business sector lies in 1 presentation of enhanced items, though the IBS business sector is generally undiscovered. Comfort, adequacy, security, and bearableness 2 are fundamental to the accomplishment of new treatments. More medication treatments must be created for 3 IBD patients who come up short first line treatments. Gastrointestinal inside scatters influence a 4 extensive populace over a wide demographic. Techniques to streamline tolerant adherence to 5 treatment could significantly enhance general clinical results and item achievement. Source: Frost & Sullivan analysis.NBB6-52 6. Market Overview—Segmentation Total Bowel Disorders Prescription Pharmaceuticals Market: Market Segmentation, U.S., 2011 Total Bowel Disorders Prescription Pharmaceuticals Market IBS IBD IBS-C IBS-D CD* UC* Oral or Injectable Treatments Topical Treatments***Considered by and large in forecasts** Not assessed in this exploration Source: Frost & Sullivan examination. NBB6-52 7. Market Overview—Segmentation (proceeded with) Total Bowel Disorders Prescription Pharmaceuticals Market: IBD Market Segmentation, U.S., 2011 Inflammatory Bowel Disease Prescription Pharmaceuticals Market CD UC Oral or Injectable Treatments Topical Treatments* 5-ASA Antibiotics* Corticosteroid Antimetabolite* Biologicals Novel Orals** ASA Corticosteroid TNFs Non-TNF Biologicals•Not secured in this examination service** Investigational; none yet sanction for IBD Source: Frost & Sullivan investigation. NBB6-52 8. Market Overview—Segmentation (proceeded with) Total Bowel Disorders Prescription Pharmaceuticals Market: IBS Market Segmentation, U.S., 2011 Irritable Bowel Syndrome Prescription Pharmaceuticals Market IBS-C IBS-M* IBS-D 5-HT3 (serotonin) Chloride channel (ClC-2) activator (diuretic) adversary Guanylate cyclase sort C receptor agonist*Not secured in this exploration benefit because of absence of sanction therapiesNote: Subsegmentation of the IBS business sector portion is not gave because of low level of business movement Source: Frost & Sullivan examination. NBB6-52 9. Market Overview—Segmentation (proceeded with) Total Bowel Disorders Prescription Pharmaceuticals Market: Percent Sales Breakdown by Drug Class, U.S., 2011 IBS-C Drugs, 5.5% IBS-D Drugs, 1.1% Corticosteroids, 8.6 % TNF inhibitors, 48.7% Biologicals, 49.5% 5-ASA, 35.3% Non-TNF biologicals, 0.8% Note: All figures are adjusted. The base year is 2011. Source: Frost & Sullivan analysis.NBB6-52
Просмотров: 22 DailySlides
Inside the $160B Pfizer-Allergan Record Deal
 
02:56
Nov. 23 -- Pfizer Inc. and Allergan Plc said they would combine operations in a stock transaction worth about $160 billion, creating a drugmaking behemoth with products from Viagra to Botox and a low-cost tax base. Jefferies Chief Market Strategist David Zervos and Bloomberg's Cynthia Koons speak on "Bloomberg ‹GO›."
Просмотров: 4749 Bloomberg
The Truth About Cancer: A Global Quest - Episode 2
 
01:25:30
!! Free "A Global Quest" Episode 2!! "Cancer-Facts And Fictions, Breast Cancer, Hormones, Skin Cancer & Essential Oil" If you would like to support our mission and own all Episodes of this eye-opening Docu-Series, please follow this link: http://bit.ly/agq-silver-order --------------------------------------------------- Welcome to Episode 2 of "The Truth About Cancer: A Global Quest". This Episode is about Cancer Facts And Fictions, Breast Cancer, Hormones, Skin Cancer & Essential Oils. We welcome you to watch this Episode completely free. If you would like to support our mission and own all Episodes of this eye-opening Docu-Series, please follow this link: http://bit.ly/agq-silver-order To watch Episode 1 of "A Global Quest" docu-series for FREE, click here: https://youtu.be/KqJAzQe7_0g Join TTAC's 1M+ FB fans: http://bit.ly/agq-fb-ttac Follow us on PINTEREST: http://bit.ly/agq-pinterest-ttac Find us on INSTAGRAM: http://bit.ly/agq-ig-ttac Visit our website: http://bit.ly/agq-website-ttac Our mission is to educate the world, expose lies & empower people with life-saving knowledge. Help us and share the truth, by clicking the SHARE button above! -------------------------------------------------- About The Truth About Cancer -------------------------------------------------- The Truth About Cancer’s mission is to inform, educate, and eradicate the pandemic of cancer in our modern world. Every single day, tens of thousands of people just like you are curing cancer (and/or preventing it) from destroying their bodies. It’s time to take matters into your own hands and educate yourself on real cancer prevention and treatments. It could save your life or the life of someone you love. ---------------------------------------------------------------------- Inside The Truth About Cancer Docu-Series --------------------------------------------------------------------- Doctors, researchers, experts, and survivors show you exactly how to prevent and treat cancer in our 3 original docu-series: "The Quest For The Cures”, “The Quest For The Cures Continues”, “The Truth About Cancer: A Global Quest”, and on our website: http://bit.ly/agq-website-ttac In our docu-series, you’ll travel with Ty Bollinger who lost both his mother and father to cancer (as well as 5 other family members). Ty travels the country and the globe and sits down with the foremost doctors, researchers, experts, and cancer conquerers to find out their proven methods for preventing and treating cancer. Please join our email list to be notified of all upcoming events (including free airings of our docu-series): http://bit.ly/join-ttac-mission Learn more about our latest docu-series “The Truth About Cancer: A Global Quest” here: http://bit.ly/free-signup-agq --------------------------------------- About Ty Bollinger --------------------------------------- Ty Bollinger is a devoted husband, father, a best-selling author, and a Christian. He is also a licensed CPA, health freedom advocate, cancer researcher, former competitive bodybuilder, and author of the best-selling book "Cancer - Step Outside the Box," which has sold over 100,000 copies worldwide. After losing his mother and father and several family members to cancer, Ty’s heartbreak and grief coupled with his firm belief that chemotherapy, radiation, and surgery were the NOT the most effective treatments available for cancer patients led him on a path of discovery. He began a quest to learn everything he possibly could about alternative cancer treatments and the medical industry. What he uncovered was shocking. On his journey, he’s interviewed cutting-edge scientists, leading alternative doctors, and groundbreaking researchers to learn about hidden alternative cancer treatments. What he uncovered help to create The Truth About Cancer and its 3 awe-inspiring docu-series’: ”The Quest for The Cures”, “The Quest For The Cures Continues”, and “The Truth About Cancer: A Global Quest.” Ty has touched the hearts and changed the lives of thousands of people around the world. Ty speaks frequently at conferences, local health group meetings, churches, and is a regular guest on multiple radio and TV shows and writes for numerous magazines and websites.
Просмотров: 2046018 The Truth About Cancer
Pope Knows Best: Climate Action Is Imperative and a Responsibility - The Ring Of Fire
 
08:09
Pope Francis’ visit to the United States came with a clear message for U.S. Congress, and it preached resistance to their warmonger mentality, hatred, bigotry, and unwillingness to help those in need. He also briefly talked about climate change, and how action on it could make a huge difference. The Pope made it clear that the ideas he promotes aren’t liberal agendas, but human and moral responsibilities. Ring of Fire’s Sam Seder and Farron Cousins discuss why such climate inaction is prevalent in the United States. Follow more of our stories at http://www.RingofFireRadio.com Spread the word! LIKE and SHARE this video or leave a comment to help direct attention to the stories that matter. And SUBSCRIBE to stay connected with Ring of Fire's video content! Listen to Ring of Fire on Saturdays from 3pm - 6pm Eastern! Listen live via the Progressive Voices Channel on TuneIn: http://tunein.com/radio/Progressive-Voices-s189055/ Or find a station here: http://www.ringoffireradio.com/station/ Watch Ring of Fire every weekday at 8:30pm EST on Free Speech TV! Support Ring of Fire by subscribing to our YouTube channel: http://www.youtube.com/user/golefttv You can also support us here: http://www.ringoffireradio.com/support/ Your continued support keeps Ring of Fire on the air! Be sociable! Follow us on: Facebook: http://www.facebook.com/RingofFireRadio Twitter: http://www.twitter.com/RingofFireRadio Google+: http://plus.google.com/118415831573195648557 Support us further by shopping on Amazon via our Amazon-Ring of Fire partnership link. A portion of the sales will come back to Ring of Fire at no extra cost to you. Bookmark and follow the link below and continue shopping as usual! Amazon - Ring of Fire partnership link: http://www.amazon.com/?tag=rinoffir-20
Просмотров: 1186 The Ring of Fire
NHALE Inc. (OTC- NHLE) Marijuana Acquisition Company
 
01:09
NHALE Inc (Symbol NHLE) is a U.S. company actively pursuing acquisition opportunities in the rapidly expanding marijuana industry. Nhale acquires companies positioned to make a significant impact within the domestic medical and recreational cannabis market. Nhale provides emerging, proven companies with access to operating talent, tools and leadership to assist in raising their position from start-ups to robust brand leaders.
Просмотров: 502 NHALE Inc
Perry’s Wealthy Donors Want Their Money Back: Sorry Millionaires, Buyers Beware - The Ring Of Fire
 
01:25
Rick Perry might not be running for president anymore, but he’s still sitting on millions of dollars of Super PAC money. He has several options about what he can do with this money, but his donors have issued a stern message to him: We want our money back. Specifically, Doug Deason, the son of Darwin Deason – a donor who gave Perry’s Super PAC $5 million, said that his father expects the money to be returned. But the Super PAC, called the Opportunity and Freedom PAC, said that they don’t have any firm plans just yet, and they’re discussing their options with their team of lawyers right now. Follow more of our stories at http://www.RingofFireRadio.com Spread the word! LIKE and SHARE this video or leave a comment to help direct attention to the stories that matter. And SUBSCRIBE to stay connected with Ring of Fire's video content! Listen to Ring of Fire on Saturdays from 3pm - 6pm Eastern! Listen live via the Progressive Voices Channel on TuneIn: http://tunein.com/radio/Progressive-Voices-s189055/ Or find a station here: http://www.ringoffireradio.com/station/ Watch Ring of Fire every weekday at 8:30pm EST on Free Speech TV! Support Ring of Fire by subscribing to our YouTube channel: http://www.youtube.com/user/golefttv You can also support us here: http://www.ringoffireradio.com/support/ Your continued support keeps Ring of Fire on the air! Be sociable! Follow us on: Facebook: http://www.facebook.com/RingofFireRadio Twitter: http://www.twitter.com/RingofFireRadio Google+: http://plus.google.com/118415831573195648557 Support us further by shopping on Amazon via our Amazon-Ring of Fire partnership link. A portion of the sales will come back to Ring of Fire at no extra cost to you. Bookmark and follow the link below and continue shopping as usual! Amazon - Ring of Fire partnership link: http://www.amazon.com/?tag=rinoffir-20
Просмотров: 2036 The Ring of Fire
Country’s Largest Telecoms Are Giving The Government Your Personal Data - The Ring Of Fire
 
07:17
AT&T is one of the top companies helping the NSA collect the private data of U.S. citizens. Not once during the Republican debates has the issue of domestic spying been brought up, but the problem just seems to be getting worse Michael Burg will tell us how telecom giant AT&T is helping the NSA get their hands on your private data, and why the issue of domestic spying is being overshadowed in this election cycle. Follow more of our stories at http://www.RingofFireRadio.com Spread the word! LIKE and SHARE this video or leave a comment to help direct attention to the stories that matter. And SUBSCRIBE to stay connected with Ring of Fire's video content! Listen to Ring of Fire on Saturdays from 3pm - 6pm Eastern! Listen live via the Progressive Voices Channel on TuneIn: http://tunein.com/radio/Progressive-Voices-s189055/ Or find a station here: http://www.ringoffireradio.com/station/ Watch Ring of Fire every weekday at 8:30pm EST on Free Speech TV! Support Ring of Fire by subscribing to our YouTube channel: http://www.youtube.com/user/golefttv You can also support us here: http://www.ringoffireradio.com/support/ Your continued support keeps Ring of Fire on the air! Be sociable! Follow us on: Facebook: http://www.facebook.com/RingofFireRadio Twitter: http://www.twitter.com/RingofFireRadio Google+: http://plus.google.com/118415831573195648557 Support us further by shopping on Amazon via our Amazon-Ring of Fire partnership link. A portion of the sales will come back to Ring of Fire at no extra cost to you. Bookmark and follow the link below and continue shopping as usual! Amazon - Ring of Fire partnership link: http://www.amazon.com/?tag=rinoffir-20
Просмотров: 598 The Ring of Fire
How Big Oil Conquered the World
 
01:11:27
TRANSCRIPT AND SOURCES: https://www.corbettreport.com/?p=16888 From farm to pharmaceutical, diesel truck to dinner plate, pipeline to plastic product, it is impossible to think of an area of our modern-day lives that is not affected by the oil industry. The story of oil is the story of the modern world. And this is the story of those who helped shape that world, and how the oil-igarchy they created is on the verge of monopolizing life itself.
Просмотров: 1103641 corbettreport
SKF India- Pune Factory
 
07:12
SKF's Pune factory is one among the more than 90 SKF production facilities around the world, that work tirelessly to meet the ever increasing global demand of high quality SKF bearings. While the people in the Pune factory come from a spectrum of diverse cultures and speak different languages, there is one overriding feature that unites them all: SKF Quality.
Просмотров: 236382 Lovina Raymond